Selecta Biosciences, a clinical-stage biotechnology company developing novel drugs that use immune-modulating nanomedicines based on Synthetic Vaccine Particles (SVP™), announced today that it has been awarded a $3.2 Million grant from Skolkovo Foundation in support of Selecta’s program to develop … Continued
Selecta Biosciences, Inc., and JDRF, announced today that they have extended their joint research collaboration and attracted Sanofi as a partner in support of their program to develop a Synthetic Vaccine Particle (SVP™) immunotherapy with the long-term goal to treat … Continued
Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today announced it has secured equity funding of more than $20 million from new and all of Selecta’s existing investors. “With strong financial … Continued
The American engineer Eric Drexler, who coined the term nanotechnology in the 1980s, is not afraid of ambitious thinking. In his 2013 book Radical Abundance: How a Revolution in Nanotechnology Will Change Civilization, Drexler imagines a 3D printer-like “factory in … Continued
SBA Materials Inc., a leader in development of engineered nano-structured material, has announced the successful closing of its Series C financing round. New investors in this round were Samsung Venture Investment Corporation (SVIC) and Sun Mountain Capital. Also participating were … Continued
Emulate, Inc. today announced the company’s launch with a $12 million Series A financing to commercialize a first-in-kind, automated ‘Organs-on-Chips’ platform that mimics human physiology and diseases, while permitting real-time elucidation of molecular mechanisms of action and toxicity. Emulate’s proprietary … Continued
View, the leader in dynamic glass, today announced it has named Mark Mendenhall as its chief commercial officer. An accomplished executive with more than three decades of innovation and leadership experience in the energy and electronics industries, Mendenhall will be … Continued
View showcased by The Guardian as a Top 10 sustainability innovation. The Guardian
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced that it has entered into a research agreement with Roche to discover novel nanomedicines using Accurins for the treatment of diseases … Continued
Selecta Biosciences, Inc.,a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today provided an update on the company’s product development pipeline, revealing its focus on immune tolerance applications of its proprietary Synthetic Vaccine Particle (SVP) … Continued